Rabbit Polyclonal BXB antibody. Suitable for WB and reacts with Clostridium botulinum samples. Cited in 1 publication.
IgG
Rabbit
Standard buffer
Polyclonal
WB | |
---|---|
Clostridium botulinum | Expected |
Species | Dilution info | Notes |
---|---|---|
Species Clostridium botulinum | Dilution info 1/1000 | Notes - |
Botulinum neurotoxin type BBotulinum toxin causes flaccid paralysis by inhibiting neurotransmitter (acetylcholine) release from the presynaptic membranes of nerve terminals of the eukaryotic host skeletal and autonomic nervous system, with frequent heart or respiratory failure. Precursor of botulinum neurotoxin B which has 2 coreceptors; complex polysialylated gangliosides found on neural tissue and specific membrane-anchored proteins found in synaptic vesicles (PubMed:17167418, PubMed:17167421, PubMed:17185412, PubMed:23807078). Receptor proteins are exposed on host presynaptic cell membrane during neurotransmitter release, when the toxin heavy chain (HC) binds to them (PubMed:14504267). Upon synaptic vesicle recycling the toxin is taken up via the endocytic pathway (PubMed:14504267). When the pH of the toxin-containing endosome drops a structural rearrangement occurs so that the N-terminus of the HC forms pores that allows the light chain (LC) to translocate into the cytosol (PubMed:3856850). Once in the cytosol the disulfide bond linking the 2 subunits is reduced and LC cleaves its target protein on synaptic vesicles, preventing their fusion with the cytoplasmic membrane and thus neurotransmitter release. Binds to host peripheral neuronal presynaptic membranes via synaptotagmins 1 and 2 (SYT1 and SYT2) (PubMed:14504267, PubMed:8144634). Toxin binds to the membrane proximal extra-cytoplasmic region of host SYT1 and SYT2 that is transiently exposed outside of cells during exocytosis; exogenous gangliosides enhance binding and subsequent uptake of toxin into host cells (PubMed:14504267, PubMed:15123599). Toxin uptake into neural cells requires stimulation (incubation with K(+) to stimulate SYT protein receptor exposure); subsequently the toxin colocalizes with its receptor in host cells with a concomitant decrease in target protein (synaptobrevin-2/VAMP2) immunoreactivity (PubMed:14504267). Toxin uptake can be blocked by the appropriate synaptotagmin protein fragments and gangliosides in cell culture and in mice (PubMed:14504267, PubMed:15123599). BoNT/B is a 'coincidence detector'; it requires simultaneous binding to coreceptor GT1b and low pH to transform into a membrane-bound, oligomeric channel (PubMed:21925111, PubMed:22720883). Whole toxin only has protease activity after reduction which releases LC (PubMed:1331807, PubMed:7803399).Botulinum neurotoxin B light chainHas proteolytic activity (PubMed:1331807). After translocation into the eukaryotic host cytosol, inhibits neurotransmitter release by acting as a zinc endopeptidase that cleaves the '76-Gln-|-Phe-77' bond of synaptobrevin-2/VAMP2, blocking neurotransmitter release (PubMed:1331807, PubMed:7803399). In vitro the LC only has protease activity after reduction (PubMed:1331807, PubMed:7803399).Botulinum neurotoxin B heavy chainResponsible for host epithelial cell transcytosis, host nerve cell targeting and translocation of light chain (LC) into host cytosol. Composed of 3 subdomains; the translocation domain (TD), and N-terminus and C-terminus of the receptor-binding domain (RBD). The N-terminus of the TD wraps an extended belt around the perimeter of the LC; it does not seem to protect the active site, but might prevent premature LC dissociation from the translocation channel and protect toxin prior to translocation (PubMed:10932256, PubMed:17167418). Has 2 coreceptors; complex gangliosides found primarily on neural tissue and host synaptotagmin-1 and -2 (SYT1 and SYT2) which bind simultaneously to adjacent but separate sites at the tip of the HC (PubMed:17167418, PubMed:17167421, PubMed:17185412, PubMed:23807078, PubMed:8144634). HC alone partially prevents uptake of whole toxin by neural cells, and delays paralysis onset by 160% (PubMed:10413679). Binding probably positions the TD for integration into the synaptic vesicle membrane (PubMed:17167418, PubMed:23807078). The HC forms channels at low pH that mediate transport of the light chain (LC) from the endocytic vesicle to the cytosol (PubMed:3856850). Binds gangliosides GD1b and GT1b (PubMed:10413679, PubMed:14731268). Gangliosides are not only a coreceptor, but also required for uptake into nerve cells (PubMed:17167418, PubMed:21925111). HC alone binds to host receptor proteins SYT1 and SYT2 (PubMed:14504267, PubMed:15123599, PubMed:17185412, PubMed:19650874). Interaction with SYT1 protein does not require SYT1 glycosylation (PubMed:19476346). The HC C-terminus (approximately residues 1079-1291) interacts with host SYT2 (PubMed:15123599, PubMed:17167418, PubMed:17167421, PubMed:23807078). Has higher affinity for SYT2 than SYT1 (PubMed:17167421, PubMed:17185412). Significantly decreases uptake and toxicity of whole BoNT/B and BoNT/G (PubMed:19650874).
Botulinum neurotoxin type B, BoNT/B, Bontoxilysin-B, botB
Rabbit Polyclonal BXB antibody. Suitable for WB and reacts with Clostridium botulinum samples. Cited in 1 publication.
IgG
Rabbit
Standard buffer
Polyclonal
Whole antiserum
Blue Ice
-20°C
Upon delivery aliquot
Avoid freeze / thaw cycle
Abcam is leading the way to address reproducibility in scientific research with our highly validated recombinant monoclonal and recombinant multiclonal antibodies. Search & select one of Abcam's thousands of recombinant alternatives to eliminate batch-variability and unnecessary animal use.
If you do not find a host species to meet your needs, our catalogue and custom Chimeric range provides scientists the specificity of Abcam's RabMAbs in the species backbone of your choice. Remember to also review our range of edited cell lines, proteins and biochemicals relevant to your target that may help you further your research goals.
Abcam antibodies are extensively validated in a wide range of species and applications, so please check the reagent specifications meet your scientific needs before purchasing. If you have any questions or bespoke requirements, simply visit the Contact Us page to send us an inquiry or contact our Support Team ahead of purchase.
This supplementary information is collated from multiple sources and compiled automatically.
Clostridium botulinum type B toxoid often referred to as botulinum toxoid B is a modified and inactive form of the botulinum neurotoxin. This toxoid is derived from Clostridium botulinum a gram-positive anaerobic bacterium. The original botulinum neurotoxin has a mass of approximately 150 kDa and is expressed in environments where the bacterium resides such as poorly processed canned foods. The inactivated form used in toxoids loses its toxicity while retaining the antigenic properties needed for eliciting an immune response.
Clostridium botulinum type B toxoid stimulates the immune system to produce antibodies that target the neurotoxin. The inactive form of the toxin functions as an immunogen allowing the body to recognize and respond to potential exposure to the live neurotoxin. As part of vaccine preparations this toxoid is used to prevent botulism a serious and sometimes lethal condition caused by the neurotoxin's interference with muscular contraction by blocking neurotransmitter release at neuromuscular junctions.
Botulinum toxoid B primarily acts indirectly by inducing an immune response rather than altering metabolic pathways directly. Its interaction with the immune system forms part of a defense pathway creating specific antibodies that neutralize the toxin before it can inhibit the function of SNARE proteins involved in neurotransmitter release. Understanding the toxoid's mechanism within the immune system highlights connections to proteins such as those in the IgG class which are essential for constructing a protective antibody response.
Clostridium botulinum type B toxoid is significant in the prevention of botulism and potentially in neuromuscular disorders where immunization against the botulinum toxin may be beneficial. Botulism is a major concern due to its impact on neuromuscular function leading to paralysis if treatment is not initiated. The toxoid's involvement in preventing the disease also implies relevance to specific muscular disorders where toxin exposure could exacerbate symptoms and understanding its interplay with immune-related proteins like IgG sheds light on therapeutic approaches.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com